compounded tirzepatide risks fda Zepbound copycats remain online despite ban Compounded Semaglutide & Tirzepatide 2025:

N Engl J Med 375:311322 Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes

Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Select your preferred medication and dosage

Despite initial pharmaceutical interest, AOD 9604 did not progress through the full clinical trial pathway required for regulatory approval, and it holds no Marketing Authorisation (MA) from the MHRA or EMA

For most people, noticeable results start appearing around the first month, with continued progress over three to six months

Why this matters for you: The availability of compounded GLP-1s is tied to a regulatory and supply reality that can change